首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Clinical Pharmacology & Therapeutics

Clinical Pharmacology & Therapeutics杂志,由Wiley-Blackwell出版,于1960年创刊,Monthly,出版语言English,ISSN:0009-9236,E-ISSN:1532-6535。

投稿咨询
Clinical Pharmacology & Therapeutics
Clinical Pharmacology & Therapeutics
Clinical Pharmacology & Therapeutics
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
4.9
CiteScore
9.9
期刊收录
SCI、SCIE

Clinical Pharmacology & Therapeutics(中文译名:《临床药理学与治疗学》),ISSN:0009-9236,EISSN:1532-6535,是Wiley-Blackwell出版的国际性学术期刊,创刊于1960年,以Monthly形式稳定发行,2026年总发文量约305篇。该刊采用非OA开放访问,学科归属为医学 - 药学。该刊是医学、药学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达4.9,2025年期刊CiteScore为9.9,2025年期刊自引率约10.2%,在中科院期刊分区体系中位列医学大类2区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Clinical Pharmacology & Therapeutics长期聚焦医学、药学及相关产业的技术应用前沿,平均审稿周期约2月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、药学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USAEngland、Netherlands、GERMANY (FED REP GER)、Switzerland、Canada、Japan等为核心发文国家与地区;US FOOD & DRUG ADMINISTRATION (FDA)UNIVERSITY OF CALIFORNIA SYSTEM、STATE UNIVERSITY SYSTEM OF FLORIDA、PFIZER、ASTRAZENECA、ROCHE HOLDING、MERCK & COMPANY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
PHARMACOLOGY & PHARMACY 药学
1区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
PHARMACOLOGY & PHARMACY 药学
1区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
PHARMACOLOGY & PHARMACY 药学
1区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q1 74 / 356

79.4

学科:PHARMACOLOGY & PHARMACY SCIE Q1 53 / 356

85.25

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:PHARMACOLOGY & PHARMACY SCIE Q1 34 / 352

90.5

学科:PHARMACOLOGY & PHARMACY SCIE Q1 26 / 353

92.78


中国学者近期发文

1
Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real-World Databases from Korea and Taiwa

Author:Ko, Hwa Yeon; Au, Philip C. M.; Cheng, Michael Chun-Yuan; Cheung, Ching-Lung; Choi, Ahhyung; Hsieh, Miyuki Hsing-Chun; Jeong, Han Eol; Lai, Edward Chia-Cheng; Li, Brian Meng-Hsun; Man, Kenneth K. C.; Rassen, Jeremy A.; Tsai, Daniel Hsiang-Te; Wang, Shirley V.; Wong, Ian C. K.; Shin, Ju-Young; Park, Sohee

Journal: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2026; Vol. 119, Issue 5, pp. 1265-1274. DOI: 10.1002/cpt.70027

2
Safety, Tolerability, and Pharmacokinetics of GMDTC for Cadmium Poisoning: A Randomized Phase 1a/1b Tria

Author:Ren, Xuefeng; Hu, Wei; Deng, Xiaobin; Ma, Rong; Pei, Fang; Chen, Xushen; Wang, Xuemei; Tang, Jixin; Lai, Yan; Pan, Shangming; Zhong, Zhiyong; Fu, Sheng; Yuan, Huamin; Yuan, Juan; Huang, Chuntao; Zeng, Yuan; Ying, Xiaodong; Dong, Guanghui; Zhang, Jinxin; Zhao, Jinyuan; Lin, Kangguang; Tang, Xiaojiang

Journal: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1002/cpt.70275

3
CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real-World Settin

Author:Park, Yoomi; Zhou, Yitian; Lauschke, Volker M

Journal: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1002/cpt.70285

4
Epidemiological Characteristics, Target Distribution, and Clinical Value of Targeted Anticancer Drugs Approved in China: A Cross-Sectional Stud

Author:Zhu, Ting; Wang, Renjie; Huang, Yafang

Journal: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1002/cpt.70296

5
Reframing the Rescue Window: From Physiological Upper Bounds to Actionable Threshold

Author:Sun, Man; Zang, Dan; Chen, Jun

Journal: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1002/cpt.70247

6
Comparing the Efficacy of Various Treatment Strategies for Patients With Advanced Triple-Negative Breast Cancer: An Umbrella Revie

Author:Ma, Xiaolan; Jia, Shubing; Gao, Tong; Liu, Jirui; Xin, Tiantian; Liu, Zhendong; Yang, Yue; Xiang, Rongwu; Gao, Mingyu; Zhao, Mingyi

Journal: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2026; Vol. , Issue , pp. -. DOI: 10.1002/cpt.70216

7
POPULATION PHARMACOKINETIC MODELING OF ZEPRUMETOSTAT IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOM

Author:Zhu, Z.; Li, S.; Zhu, M.; Djeblii, N

Journal: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2026; Vol. 119, Issue , pp. -. DOI:

8
POPULATION PHARMACOKINETIC MODELING OF FUZULOPA-RIB IN PATIENTS WITH VARIOUS CANCER TYPES INCLUDING METASTATIC CASTRATION- RESISTANT PROSTATE CANCE

Author:Zhu, Z.; Li, S.; Djebli, N

Journal: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2026; Vol. 119, Issue , pp. -. DOI:

9
EXPOSURE- RESPONSE ANALYSIS TO PREDICT DIARRHEA FOR NOVEL DUAL GLP-1/GIP RECEPTOR AGONIST HRS9531 BASED ON LOGISTIC REGRESSION AND DISCRETE-TIME MARKOV MODLEIN

Author:Wang, Y.; Wang, J.; Chen, P.; Zhang, Y.; Zuo, Y.; Zhang, L.; Zeng, M.; Djebli, N

Journal: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2026; Vol. 119, Issue , pp. -. DOI:

10
A POPPK-BASED MIDD APPROACH TO SUPPORT TRANSITION FROM BODY WEIGHT-BASED TO FLAT DOSING FOR A NOVEL ANTI- CTLA-4 MONOCLONAL ANTIBODY SHR-8068 IN AD-VANCED HEPATOCELLULAR CARCINOM

Author:Wang, Y.; Zhang, Y.; Chen, P.; Yang, Q.; Yu, M.; Sun, Y.; Wang, S.; Djebli, N

Journal: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2026; Vol. 119, Issue , pp. -. DOI:


在线咨询

Clinical Pharmacology & Therapeutics

国际简称:CLIN PHARMACOL THER参考译名:临床药理学与治疗学

年发文量:305 CiteScore:9.9 是否预警:否 Gold OA文章占比:53.38% 研究类文章占比:79.02%

杂志社联系方式:NATURE PUBLISHING GROUP, 75 VARICK ST, 9TH FLR, NEW YORK, USA, NY, 10013-1917

Clinical Pharmacology & Therapeutics